

# B Cell Development in the Spleen Takes Place in Discrete Steps and Is Determined by the Quality of B Cell Receptor-derived Signals

By Florienne Loder,\* Bettina Mutschler,\* Robert J. Ray,<sup>§</sup>  
Christopher J. Paige,<sup>§</sup> Paschalis Sideras,<sup>||</sup> Raul Torres,<sup>¶</sup>  
Marinus C. Lamers,<sup>‡</sup> and Rita Carsetti\*

From the \*Department of Molecular Immunology, Institute of Biology III, University of Freiburg, and the Max-Planck-Institute for Immunobiology, D-79108 Freiburg, Germany; the †Department of Developmental Immunology, Max-Planck-Institute for Immunobiology, D-79108 Freiburg, Germany; the §Wellesley Hospital Research Institute, Toronto, Ontario M4Y 1J3, Canada; the ||Department of Applied Cellular and Molecular Biology, Umeå University, S-901 87 Umeå, Sweden; and the ¶Basel Institute for Immunology, 4005 Basel, Switzerland

## Summary

Only mature B lymphocytes can enter the lymphoid follicles of spleen and lymph nodes and thus efficiently participate in the immune response. Mature, long-lived B lymphocytes derive from short-lived precursors generated in the bone marrow. We show that selection into the mature pool is an active process and takes place in the spleen. Two populations of splenic B cells were identified as precursors for mature B cells. Transitional B cells of type 1 (T1) are recent immigrants from the bone marrow. They develop into the transitional B cells of type 2 (T2), which are cycling and found exclusively in the primary follicles of the spleen. Mature B cells can be generated from T1 or T2 B cells.

Mice with genetic deletions of elements participating in the B cell receptor signaling cascade display developmental arrest at the T1 or T2 stage. The analysis of these defects showed that the development of T2 and mature B cells from T1 precursors requires defined qualitative and quantitative signals derived from the B cell receptor and that the induction of longevity and maturation requires different signals.

Key words: B cell development • transitional B cells • spleen • CD45 • Bruton's tyrosine kinase

In the adult mouse, B cells are generated in the bone marrow. Their development requires the successful rearrangement of the Ig H and L chain gene loci and the surface expression of the B cell antigen receptor (BCR)<sup>1</sup> (1).

The BCR is composed of the membrane-bound Ig molecule and the Ig- $\alpha$ /Ig- $\beta$  heterodimer. The Ig- $\alpha$ /Ig- $\beta$  heterodimer is indispensable for the surface expression and signaling function of the BCR (2). In the early phases of development in the bone marrow, B cells only express IgM. Immature B cells have a low density of IgM (IgM<sup>dull</sup>) and are still resident in the parenchyma of the bone marrow. They develop into IgM<sup>bright</sup> transitional B cells (3) and move toward and through the bone marrow sinusoids before migrating to the periphery (4). Few of the transitional

B cells enter the mature, long-lived B cell compartment. Out of the  $2 \times 10^7$  IgM<sup>+</sup> B cells that develop daily in the bone marrow of the mouse, 10% reach the spleen and only 1–3% enter the mature B cell pool (5, 6). Mature B cells coexpress IgM and IgD (7). IgM<sup>+</sup>IgD<sup>+</sup> B cells in the bone marrow are thought to be B cells that have completed their maturation process in the periphery and return to the bone marrow as mature recirculating B cells. In the normal mouse, only mature B cells are long lived, can recirculate with the lymph and the blood, and are able to enter the lymphoid follicles of spleen and lymph nodes. These abilities are very important to mount an efficient immune response. Only B cells that can enter the follicle have access to antigen deposited on the follicular dendritic cells and are able to initiate the germinal center reaction and then rapidly produce antigen-specific, high-affinity Abs.

The rules that regulate the size, diversity, and quality of the long-lived B cell pool are therefore important but largely unknown. It is, however, likely that signals from the BCR control these differentiation events (8–11). Indeed, mice with

<sup>1</sup>Abbreviations used in this paper: BCR, B cell antigen receptor; BrdU, bromodeoxyuridine; Btk, Bruton's tyrosine kinase; HSA, heat-stable antigen; MAP, mitogen-activated protein; MZ, marginal zone; PALS, periarteriolar lymphoid sheath; PH, plekstrin homology; PKC, protein kinase C; T1, transitional type 1; T2, transitional type 2.

natural or targeted deletions or mutations of genes encoding elements involved in BCR signaling often show abnormal development of B cells and are therefore useful tools to study the molecular requirements for lymphocyte differentiation.

The deletion of the cytoplasmic part of Ig- $\alpha$  in mb1  $\Delta c/\Delta c$  mice (12) still permits expression of the IgM-BCR on the cell surface, and B cell development in the bone marrow is compromised but not completely blocked. However, the mature B cell pool is absent in the periphery.

CD45 is a tyrosine phosphatase expressed in alternatively spliced forms on the surface of B and T cells and cells of the myeloid lineage. In mice deficient for CD45 (13), thymocyte development is blocked at the CD4, CD8 double-positive stage. The early stages of B cell differentiation in the bone marrow are normal, but B cell development is blocked in the spleen (14). CD45 positively regulates BCR signaling. In B cells deficient for CD45, BCR cross-linking fails to elicit calcium influxes from the extracellular space and induce B cell proliferation (14). These defects can be explained at least partially by the positive regulatory role that CD45 exerts on the Src family kinase Lyn. Lyn plays a fundamental role in BCR signaling (15).

Bruton's tyrosine kinase (Btk) is a 77-kD nonreceptor tyrosine kinase that is specifically expressed in myeloid cells and B lymphocytes (16). Btk plays a complex role in BCR signaling. It is rapidly activated by Src family kinases after BCR cross-linking and interacts with a number of ligands participating in the BCR signaling cascade. Btk has an NH<sub>2</sub>-terminal plekstrin homology (PH) domain that interacts with the PI-3 kinase product phosphatidylinositol (3,4,5) triphosphate (PI[3,4,5]P<sub>3</sub>) and with other signaling molecules, like protein kinase C (PKC) (17) and G proteins (18). The interaction with PI(3,4,5)P<sub>3</sub> regulates the recruitment of Btk to the cell membrane and thus the intensity and duration of extracellular calcium fluxes (19). The localization of Btk to the cell membrane might also be influenced by the interaction with PKC. PKC activity, in turn, is modulated by Btk. The association with G protein results in an increase of the catalytic activity of Btk (20). The PH domain is essential for the function of Btk. CBA/N mice, which represent the prototype for the murine X-linked immunodeficiency (xid), have a mutation (Arg28→Cys) in the PH domain (21). B cell development is blocked at an immature stage in the spleens of CBA/N mice (22); the same defect is observed in mice with a complete deletion of the Btk domain (23).

We have analyzed the late stages of B cell development in normal mice and in mice with mutations of Ig- $\alpha$ , CD45, and Btk, elements that all participate in the transduction of signals from the BCR. We confirm that specific signals derived from the BCR are indispensable for the survival of B cells that have just left the bone marrow and demonstrate that the quality of these signals regulates their further differentiation into mature, long-lived B cells.

## Materials and Methods

**Mouse Strains.** CD45<sup>-/-</sup> (13) and RAG-2<sup>-/-</sup> (24) mice have been described before (13, 21). Mutant mice and mice of stan-

dard strains (C57BL/6, CBA/J, and CBA/N) were bred and maintained in our animal facilities, with the exception of the mb1  $\Delta c/\Delta c$ -deficient (12) and the mb1  $\Delta c/\Delta c$ -CD45<sup>-/-</sup> double-mutant mice, which were bred at the Basel Institute of Immunology (Basel, Switzerland). Adult mice were 6–8 wk old.

**Flow Cytometry.** Single-cell suspensions, prepared from different organs, or peripheral blood samples were depleted of erythrocytes by lysis with Gey's solution. For three-color fluorescence surface staining, 10<sup>6</sup> cells per sample were incubated with varying combinations of FITC-, PE-, Cy5-, and biotin-labeled Abs. Streptavidin-RED670 (GIBCO BRL) was used as second-step reagent. Apoptotic cells were detected using merocyanine 540 (Sigma Chemical Co.) at 1  $\mu$ g/ml. Data was collected on a FACScan<sup>™</sup> or FACStar<sup>PLUS</sup><sup>™</sup> flow cytometer (Becton Dickinson) and analyzed using CELLQuest<sup>™</sup> software (Becton Dickinson). The following mAbs were used: anti-IgM (clone 2911), anti-IgD (clone 11.26c), anti-CD21 (clones 7G6 and 7E9), anti-CD23 (clone B3B4), anti-B220 (clone RA3-6B2), and anti-HSA (heat-stable antigen; clone M1/69). They were prepared and labeled in our laboratory or purchased from PharMingen. PE-labeled goat F(Ab)<sub>2</sub> anti-IgM was purchased from Caltag Labs., and Cy5-labeled goat anti-IgM was from Jackson ImmunoResearch Labs., Inc.

**Bromodeoxyuridine Labeling and Cell Cycle Analysis.** The thymidine analogue bromodeoxyuridine (BrdU; 1 mg/ml) was freshly prepared every day and administered in the mouse drinking water. Normal water was given after a 3–5-d labeling period. BrdU incorporated into the DNA during the application period was detected by flow cytometry, using a protocol that allowed both examination of BrdU incorporation and surface phenotype (6). At each point of measurement, two mice per experimental group were analyzed. Anti-BrdU Abs were purchased from Becton Dickinson and BrdU from Calbiochem Corp.

For cell cycle analysis, splenic and bone marrow cells were first stained with FITC- and CY5-labeled Abs directed against surface markers. Cells were then fixed with 70% ethanol. Propidium iodide (10  $\mu$ g/ml) was added after a 30-min treatment with RNase.

**Transfer Experiments.** Splenic cells from a pool of 8 and, in a second experiment, 20 1-wk-old C57BL/6 mice were depleted of erythrocytes and dead cells by density gradient centrifugation (Ficoll Paque; Pharmacia Biotech). The percentage of transitional type 1 (T1) B cells in the preparation was measured by flow cytometry. Cells were injected into the tail veins of adult RAG-2<sup>-/-</sup> mice in 200  $\mu$ l PBS. Each mouse received 2  $\times$  10<sup>6</sup> B cells.

Sorted transitional type 2 (T2) cells (10<sup>6</sup>) were injected into the tail veins of adult RAG-2<sup>-/-</sup> mice. The spleens of recipient mice were analyzed by flow cytometry after 24 and 48 h. Three independent experiments were performed.


**Histology.** Cryostatic sections (6  $\mu$ m) of spleens were fixed with cold acetone and then stained with fluorescent Abs. Slides were analyzed with a Leica Confocal Laser Scanning Microscope (model TCS 4D). For FITC, the excitation wavelength was 488 nm, and the emitted fluorescence was collected with a BP 520 filter. TRITC was excited at 568 nm and fluorescence was collected with an LP 590 filter. TRITC-labeled IgM was from Jackson ImmunoResearch Labs., Inc. and anti-MAdCAM was from PharMingen.

## Results

*Transitional B Cells of Normal Mice Can Be Separated into Two Subsets, T1 and T2, Based on Expression of IgD and CD21.* We have recently described an intermediate stage in the development of B cells in the bone marrow, the transitional B

cell stage (3), and we have shown, as later studies have confirmed (25), that transitional B cells are the target of negative selection. Transitional B cells express high amounts of IgM ( $IgM^{bright}$ ) and low amounts of IgD ( $IgD^{dull}$ ). Based on the surface expression of IgM and IgD, transitional B cells (indicated as T in Fig. 1 A) can be distinguished from  $IgM^{dull}IgD^{-}$  immature B cells and from  $IgM^{dull}IgD^{bright}$  mature B cells


(Fig. 1 A, indicated by M; prototypic mature B cells are lymph node B cells). Transitional B cells are found not only in the bone marrow but also in the blood and spleen (Fig. 1 A, top panels). In the bone marrow, 15–20% of all B lymphocytes have the phenotype of transitional B cells, whereas in the blood they are 15–20% and in the spleen 10–15% of all B cells. In the lymph node, transitional B cells are not found.



**Figure 1.** Transitional B cells of normal mice. Three-color flow cytometric analysis of cells isolated from bone marrow, blood, spleens, and lymph nodes of adult C57BL/6 mice. 100,000 events were collected. (A) Log density plots showing IgD and IgM expression. Top, all cells; center, MEL-14<sup>-</sup> cells; bottom, MEL-14<sup>+</sup> cells. M, mature B cells; T, transitional B cells. Arrows, cells that are indicated as T2 in panel B. (B) Cells were stained with Abs to IgM and CD21. M, mature B cells; T1, CD21<sup>-</sup> and T2, CD21<sup>bright</sup> transitional B cells. (C) Splenocytes were stained with Abs to IgM, IgD, and CD23. The plots show the IgD and IgM staining of cells separated on the basis of the expression of CD23. CD23<sup>-</sup> B cells include  $IgM^{bright}IgD^{-}$  T1, and MZ B cells and all  $IgM^{-}$  cells in the spleen (T cells and macrophages). Only B cells are positive for CD23. They are mostly T2 and mature (M) B cells. (D) Splenocytes were stained with Abs to IgD, CD21, and IgM and separated into  $IgD^{-}$  or  $IgD^{+}$  cells.  $IgD^{-}$  T1 and MZ B cells can be distinguished on the basis of CD21 expression. T2 and mature B cells are both in the gate of the  $IgD^{+}$  B cells but are either bright (T2) or dull (M) for IgM.

Lymphocyte entry in the lymph nodes is dependent on l-selectin, an adhesion molecule that facilitates migration through the high endothelial venules (26). We used the anti-l-selectin Ab MEL-14 to separate bone marrow, blood, spleen, and lymph node cells in MEL-14<sup>-</sup> and MEL-14<sup>+</sup> cells (Fig. 1 A, center and bottom panels, respectively). Transitional B cells were exclusively MEL-14<sup>-</sup> (Fig. 1 A, center panels, gate T). Mature B cells were instead almost all positive for MEL-14. Only a minor fraction (<10%) of the mature B cells in the spleen and lymph node was negative for MEL-14. Our analysis suggests that transitional B cells leave the bone marrow with the blood. The absence of l-selectin on transitional B cells is consistent with their inability to enter the lymph node and their preferential migration to the spleen. A second population of IgM<sup>bright</sup> B

cells is found exclusively in the spleen and expresses, in contrast to transitional B cells, both IgD and l-selectin (Fig. 1 A, arrows). We have used CD21 as a marker to further analyze this population. CD21, or complement receptor type 2 (CR-2), binds to C3 complement components (27) and is expressed in a developmentally regulated way. It is not present on immature B cells but is expressed on mature B cells. By staining with Abs to IgM and CD21, we could divide the population of IgM<sup>bright</sup> B cells into two populations, which we have called transitional 1 (T1) and transitional 2 (T2). T1 B cells lack CD21, whereas T2 B cells express CD21 in higher amounts (CD21<sup>bright</sup>) than mature B cells (Fig. 1 B). T2 B cells are found exclusively in the spleen but not in the bone marrow, blood, or lymph node (Fig. 1 B).



**Figure 2.** T1 B cells are the precursors of T2 and mature B cells. (A) Splenocytes of 1- (left) and 3- (center) wk-old and adult (right) C57BL/6 mice were stained with Abs to CD21 and IgM and analyzed by flow cytometry. (B) Splenic cells from recipient RAG-2<sup>-/-</sup> mice were analyzed at the indicated times after transfer of  $2 \times 10^6$  splenic B cells from a pool of 1-wk-old mice. Cells were stained with Abs to IgM, IgD, and CD21. Top panels, IgM vs. IgD staining. Bottom panels, the CD21 vs. IgM profile of IgD<sup>+</sup>IgM<sup>+</sup> donor B cells. 200,000 events were collected. Data is shown as dot plots to highlight the few transferred cells that home to the spleen. In the dot plots corresponding to the control (adult) spleen, only 5% of the collected events are shown.

**Relationship of T2 B Cells to Previously Described B Cell Populations.** Recently, CD21<sup>bright</sup>IgM<sup>bright</sup> B cells in the spleen have been identified as marginal zone (MZ) B cells (28). The MZ is mainly populated by B cells and macrophages and surrounds the lymphoid follicle outside the marginal sinus. MZ B cells do not express the differentiation markers IgD and CD23, which are also absent on immature and transitional B cells in the bone marrow (3). Splenic CD23<sup>-</sup> B cells are IgM<sup>bright</sup> and IgD<sup>-</sup> (Fig. 1 C, left), whereas CD23<sup>+</sup> B cells coexpress IgM and IgD (Fig. 1 C, right). A more precise discrimination of the different B cell populations in the spleen is based on comparing the expression of CD21 and IgM on IgD<sup>-</sup> or IgD<sup>+</sup> B cells (Fig. 1 D). IgM<sup>bright</sup>IgD<sup>-</sup> B cells include T1 B cells, which are CD21<sup>-</sup>, and MZ B cells, which are CD21<sup>bright</sup> (Fig. 1 D, left). IgM<sup>+</sup>IgD<sup>+</sup> B cells include T2 and mature B cells (Fig. 1 D, right). Therefore, we can identify two populations of IgM<sup>bright</sup>CD21<sup>bright</sup> B cells in the spleen: (i) the MZ B cells (3–5% of the splenic B cells), which lack IgD and CD23 and (ii) T2 B cells (15–20%), which express both IgD and CD23. T1 B cells represent 5–10% of splenic B cells, with mature B cells corresponding to the remainder.

T2 cells thus represent a distinct population of IgM<sup>bright</sup>IgD<sup>bright</sup>CD21<sup>bright</sup>CD23<sup>+</sup> B cells. This phenotype distinguishes them from T1, MZ, and mature B cells. Moreover, they are found exclusively in the spleen and not in the lymph node or bone marrow. We found T2 B cells in the spleens of adult mice of different genetic backgrounds (C57BL/6, BALB/c, CBA/J, or NMRI), independent of intentional immunization or housing conditions (conventional, specific pathogen free, and germ free; results not shown).


**T1 B Cells Are the Precursors of T2 and Mature B Cells.**

To investigate the developmental relationship between T1, T2, and mature B cells, we studied their distribution among splenocytes of mice at various ages. In the adult mouse, T1, T2, and mature B cells were present in the expected proportions (Fig. 2 A, right). In the spleens of 1-wk-old mice, all B cells were T1 B cells (Fig. 2 A, left). T2 and mature B cells started to appear at 2 wk of age (not shown) and were clearly detectable in the spleen of 3-wk-old mice (Fig. 2 A, center). At this time, the T1 population was still larger than in the adult mice (40%), and the fractions of T2 and mature B cells were reduced. MZ B cells are not present in the spleens of newborn mice; they are first detectable in the spleen at 4 wk of age (28).

To study the developmental potential of neonatal T1 B cells, we transferred splenocytes from 1-wk-old mice into adult RAG-2<sup>-/-</sup> mice, which lack B and T cells (24). Donor splenocytes were injected into the mouse tail veins, and the spleens of recipient mice were analyzed 5, 24, and 48 h after transfer. The expression patterns of IgD and IgM showed that 5 h after transfer, all donor B cells still had the T1 phenotype (Fig. 2 B, top). IgD<sup>+</sup> and IgM<sup>dull</sup> cells were found 24 h after transfer (Fig. 2 B, top). Mature B cells and T2 B cells were clearly detectable after 48 h (Fig. 2 B, top, labeled M and T2, respectively). This was confirmed by the analysis of CD21 expression on B cells (B cells were defined as being positive for IgM and/or IgD). In Fig. 2 B,

bottom, the expression patterns of CD21 and IgM are represented. 48 h after transfer, T2 B cells were 52% of all B cells, whereas mature B cells were 36% (Fig. 2 B, bottom). Both T2 and mature B cells expressed CD23 (not shown). In a second experiment, the fate of transferred cells was followed for 7 d after injection. At this time, mature and T2 B cells were still detectable, but ~50% of the transferred cells had downregulated IgD and CD23 and could be considered phenotypically MZ B cells (not shown). In both experiments, the transferred cells constituted ~1% of all splenocytes of recipient mice.

These experiments demonstrate that in the adult spleen, neonatal T1 B cells develop to T2 and mature B cells in 2 d and to MZ B cells in 7 d. Therefore, neonatal T1 B cells do not have an intrinsic defect that prevents their further maturation (29) but most likely, the microenvironment of the neonatal spleen does not support the late phases of B cell development, from T1 to T2 and to mature B cells.




**Figure 3.** T2 B cells develop into mature B cells in the spleen. (A) Spleen cells of adult mice were stained with Abs to HSA and CD21, and T1, T2, and mature (M) B cells were identified (before sort). CD21<sup>+</sup>HSA<sup>bright</sup> T2 B cells were sorted (after sort) and transferred into adult RAG-2<sup>-/-</sup> recipient mice. (B) The spleens of recipient RAG-2<sup>-/-</sup> mice were analyzed 24 h after transfer and compared with the spleen of an adult control mouse. T1, T2, and mature B cells were identified on the basis of the expression of HSA, B220, IgM, and IgD. The plots show the IgD and IgM staining of cells that were positive for B220 and either bright or dull for HSA.

**T2 B Cells Develop into Mature B Cells.** What is the developmental relationship between T2 and mature B cells? T2 and mature B cells could independently develop from the T1 population, or T2 B cells could represent an intermediate stage of development, preceding the mature stage. To address this question, we isolated T2 B cells from the spleen of a normal adult mouse, transferred them into RAG-2<sup>-/-</sup> mice, and analyzed their developmental potential. To separate T2 from T1 and mature B cells, we did not use the IgM and IgD antigen receptors as markers, because the staining procedure could have initiated BCR-mediated signals and, therefore, influenced B cell survival and differentiation. T1, T2, and mature B cells were instead identified on the basis of their expression of HSA and CD21. The expression of HSA is developmentally regulated in B cells. It is high in early phases of development in the bone marrow, and it is downregulated in mature B cells. Recent bone marrow immigrant B cells express higher amounts of HSA than mature B cells (5). By staining with Abs to HSA and CD21, we could distinguish T1, T2, and mature B cells. T1 B cells are HSA<sup>bright</sup> and lack CD21. T2 B cells are also HSA<sup>bright</sup> but express CD21, and mature B cells are HSA<sup>dull</sup> and CD21<sup>+</sup> (Fig. 3 A, before sort). In further experiments, we confirmed the accuracy of the discrimination by using IgM and IgD as additional markers (not shown). The purity of sorted T2 B cells (Fig. 3 A, after sort) was also controlled by staining an aliquot with Abs to IgM and IgD. Sorted T2 B cells expressed high amounts of both IgM and IgD and, therefore, corresponded to bona fide T2 B cells.

10<sup>6</sup> sorted HSA<sup>bright</sup>CD21<sup>+</sup> T2 B cells were injected into the tail veins of RAG-2<sup>-/-</sup> mice. Recipient mice were killed 24 h later, and splenocytes were stained with Abs to B220, HSA, IgD, and IgM. As control, a normal mouse was analyzed; the staining pattern of T1 and T2 B cells is shown in Fig. 3 B (control). Both populations were undetectable in the mice that had received the T2 transplant. At least 95% of the B cells isolated from host RAG-2<sup>-/-</sup> spleens were B220<sup>+</sup>HSA<sup>dull</sup> mature B cells (Fig. 3 B, 24 h). Three independent experiments were performed, and recipient mice were also analyzed 48 h after transplantation, always with comparable results (not shown).

Our experiments demonstrate that T2 B cells develop into mature B cells in the spleen. This step of differentiation is associated to the downregulation of IgM and HSA. Our data does not exclude the possibility that at least a fraction of the T1 B cells can also directly develop into mature B cells.

**T2 B Cells Are in the Primary Follicle.** To study the localization of T1, T2, and mature B cells in the spleens of normal mice, we stained sections with TRITC-coupled Abs to IgM and with FITC-coupled Abs to IgD (Fig. 4 A). IgM<sup>bright</sup>IgD<sup>-</sup> MZ and T1 B cells appear in red, T2 B cells, which coexpress high amounts of IgM and IgD, appear in yellow, and mature B cells, which are bright for IgD and have downregulated IgM, are green (Fig. 4). T1 B cells are in the outer periarteriolar lymphoid sheet (PALS) close to the primary follicle. T2 and mature B cells are together inside the follicle. Mature B cells can also be seen in the outer PALS and in the red pulp. MZ B cells, as expected, sur-



**Figure 4.** T2 B cells are in the primary follicle of normal mice. (A) Sections of normal spleen were fixed and stained with TRITC-labeled goat anti-mouse IgM and FITC-labeled anti-mouse IgD. Green and red fluorescence were measured separately by confocal laser microscopy, and the pictures obtained were then overlaid (magnification 100). M, mature B cells. (B) The sector indicated by the square in A was scanned with a 250-fold amplification to better visualize single cells. T1 B cells (red) are indicated by the single-headed arrow and T2 (yellow) by the double-headed arrow. Mature B cells are green.

round the follicle. Fig. 4 B shows an enlargement of the bordering area between outer PALS and follicle, where single T1 (red; indicated by the single-headed arrow) and T2 cells (yellow; indicated by the double-headed arrow) can be seen, together with mature B cells (bright green).


**B Cell Development Is Arrested at the T2 B Cell Stage in the Splens of  $CD45^{-/-}$  and CBA/N Mice.** Development of mature B cells is compromised in mice deficient for CD45 and in mice mutant for Btk (CBA/N). We stained splenocytes of normal control,  $CD45^{-/-}$ , and CBA/N mice with Abs to IgM, IgD, CD21, and CD23. Most of the splenic B cells of  $CD45^{-/-}$  and CBA/N mice are phenotypically identical to the T2 B cells of normal mice. They are IgM<sup>bright</sup>IgD<sup>bright</sup> (Fig. 5 A, gate T2) and CD23<sup>+</sup>CD21<sup>bright</sup> (Fig. 5 B, bottom panels). T2 B cells, however, are present in a higher percentage: in  $CD45^{-/-}$  mice, they represent 49% and in CBA/N mice 44% of all B cells, as compared with 15–20% in normal mice. The fraction of T1 B cells is only slightly reduced in size in  $CD45^{-/-}$  mice and is normal in CBA/N mice.

Surprisingly, MZ B cells are present in the expected proportions and have a normal phenotype in  $CD45^{-/-}$  and CBA/N

mutant mice. We calculated the percentages of T1, T2, and MZ B cells in normal and mutant mice based on the stainings shown in Fig. 5 B. In normal mice, T1 B cells (IgM<sup>bright</sup>CD23<sup>-</sup>CD21<sup>-</sup>) represent 7% and MZ B cells (IgM<sup>bright</sup>CD23<sup>-</sup>CD21<sup>+</sup>) 3% of all B cells. The fraction of T1 B cells is slightly reduced in the  $CD45^{-/-}$  spleen (4%); the fraction of MZ B cells is normal (3%). In the CBA/N mouse, both T1 and MZ B cells are slightly increased in percentage (13 and 5%, respectively). Prototypic mature B cells are not found in these mice: the cells in gate M (mature) in Fig. 5 express more IgM and CD21 than normal mature B cells.

The genetic background does not influence the distribution of T1, T2, and mature cells in the spleen, because the relative size and phenotype of the three populations is identical in normal C57BL/6 and CBA/J mice, which are genetically matched controls for  $CD45^{-/-}$  and CBA/N mice, respectively (not shown). Therefore, in all of the following experiments, we used C57BL/6 mice as controls.

Although the frequency of T2 B cells is similarly increased in  $CD45^{-/-}$  and CBA/N mice, their absolute number is dramatically different in the two mutant mice. In




**Figure 5.** B cell development is blocked at the T2 stage in  $CD45^{-/-}$  and CBA/N mice, but the number and the phenotype of MZ B cells is normal. Flow cytometric analysis of splenic B cells from normal C57BL/6 (control) and  $CD45^{-/-}$  and CBA/N mice. (A) Cells were stained with Abs to IgM and IgD. T1, T2, and mature (M) B cells are boxed. (B) Cells were stained with Abs to CD23, CD21, and IgM and separated into CD23<sup>-</sup> and CD23<sup>+</sup> cells. T1, T2, MZ, and mature B cells were identified as in Fig. 1 C. The fraction of T2 B cells represented 23% of all B cells in the normal mouse spleen, 55% in the  $CD45^{-/-}$  spleen, and 50% in the CBA/N spleen.


the spleens of CD45<sup>-/-</sup> mice, the absolute number of T2 B cells is six to eight times larger than in control mice, whereas in CBA/N mice, the size of the T2 population is normal (Fig. 6). In contrast, the total number of the phenotypically aberrant mature B cells is reduced in the CBA/N mice but normal in CD45<sup>-/-</sup> mice. These data demonstrate that the defect in B cell development that leads to an arrest at the T2 stage is not identical in the two mutant mice. To support this conclusion, we backcrossed CD45<sup>-/-</sup> to CBA/N mice. In double-mutant mice, the number of T2 B cells is five times higher and the number of mature B cells is four times lower than in normal mice (Fig. 6). These results prove that CD45 plays a role in determining the number of cells in the T2 B cell pool, whereas Btk either facilitates the entry of T2 B cells into the mature B cell pool or prolongs the survival of mature B cells.

**T2 B Cells Proliferate in the Spleen; Proliferation Is Deregulated in CD45<sup>-/-</sup> Mice.** In normal mice, mature B cells are long lived, and recent splenic immigrant B cells from the bone marrow are short lived, with a life span of 3 d after their arrival in the spleen. Subsequently, they are either incorporated into the long-lived pool or eliminated (5, 30). We determined the frequency and phenotypic distribution of short- and long-lived B cells in CD45 and Btk mutant mice using the BrdU labeling technique. Mice were analyzed 24, 72, and 120 h after the onset of the treatment. 24 h after the beginning of the BrdU administration, the fraction of labeled cells was 4% in the spleens of normal mice (Fig. 7) and rose to a maximal 16% after 3 d of continuous treatment. In CD45<sup>-/-</sup> and CBA/N mice, about half of the splenic B cells incorporated BrdU in 24 h. The percentage of labeled cells remained constant thereafter. Our results confirm the life span analysis of splenic B cells of normal mice but indicate that in mutant mice, labeled B cells have a life span of only 1 d.

Splenic B cells that are labeled after a short BrdU pulse represent the balance of (a) cells derived from cycling bone marrow precursors, (b) labeled cells that died during the treatment period, and (c) cells that entered the cell cycle in the spleen. This last factor is not considered significant in the normal mouse. However, because B cell numbers and labeling rates were normal in the bone marrow of CD45<sup>-/-</sup> mice (not shown), the large number of B cells labeled with BrdU can only be explained by proliferation in the spleen. Therefore, we studied cell cycle progression of T1, T2, and mature B cells in spleen and bone marrow. The different populations were identified by surface staining with



**Figure 6.** Absolute number of T2 and mature (M) splenic B cells in normal, CD45<sup>-/-</sup>, and CBA/N and in CD45<sup>-/-</sup> CBA/N double-mutant mice. Cell numbers were calculated using the gates shown in Fig. 5. Stippled bar, normal; gray bar, CD45<sup>-/-</sup>; black bar, CBA/N; hatched bar, double mutant.



**Figure 7.** Kinetics of BrdU labeling of B lymphocytes of normal and mutant mice. Mice received BrdU (1 mg/ml) in their drinking water for the indicated times. Splenic B cell populations were identified on the basis of three different surface staining protocols: IgM vs. IgD, IgM vs. CD21, and IgD vs. CD22. The BrdU content of the cells was determined by flow cytometry. The experiments were repeated three times, and comparable results were obtained. The columns represent the percentages of BrdU-labeled B cells in normal and mutant mice analyzed 24 (stippled bars) and 72 h (gray bars) after the beginning of the BrdU administration. The percentage of B cells still labeled 18 d after a 3-d treatment with BrdU (18-d chase; black bars) is also shown. The absolute numbers of labeled B cells in the normal spleen were  $2 \times 10^6$  after 24 h,  $5.6 \times 10^6$  after 3 d, and  $0.9 \times 10^6$  after the 18-d chase. In the CD45<sup>-/-</sup> mouse,  $35 \times 10^6$  B cells were labeled after 24 h and  $37.8 \times 10^6$  after 3 d.  $0.8 \times 10^6$  B cells were still labeled after the 18-d chase. The CBA/N mouse had  $2.4 \times 10^6$  labeled B cells on day 1 and  $3.2 \times 10^6$  on day 3. Only  $0.1 \times 10^6$  cells were still labeled after the chase.

anti-IgM and anti-CD21 Abs, and DNA content was measured with propidium iodide. As expected, in spleens and bone marrow of normal and mutant mice, 93–97% of the mature and T1 B cells are in the G0–G1 phase of the cell cycle (Table I). Surprisingly, 15% of the T2 B cells of normal mice are in the G2–M phase of the cell cycle. In CD45<sup>-/-</sup> mice, 33% and in CBA/N mice, 21% of the T2 B cells are in the G2–M phase. In this type of analysis, MZ B cells are included in the T2 B cell population. Although they represent a minor fraction, we have also measured cell cycle progression in IgM<sup>bright</sup>IgD<sup>bright</sup> (proper T2 B cells), IgM<sup>bright</sup>IgD<sup>-</sup> (T1 and MZ B cells), and IgM<sup>+</sup>IgD<sup>bright</sup> cells (mature B cells). The results confirmed the notion that T1, MZ, and mature B cells are noncycling cells, whereas the T2 B cells are a population of cycling cells (Table I, bottom). Therefore, entrance into the cell cycle appears to be a normal event at the T2 B cell stage, but proliferation is limited. In contrast, proliferation is deregulated in the absence of CD45.

**Entrance into the Mature Pool Is Impaired in CBA/N Mice.** The recruitment rate into the long-lived pool was measured by pulse–chase experiments. The fraction of BrdU-labeled B cells was measured 18 d after a 3-d labeling pulse with BrdU. As few as 14% of the B cells that had incorporated BrdU over a 3-d period entered the long-lived pool in the spleens of normal mice, compared with an even lower 2% in CD45<sup>-/-</sup> and 2% in CBA/N mice (Fig. 7). Therefore, the number of splenic B cells labeled after 3 d of continuous BrdU administration corresponds to the number

**Table I.** Cell Cycle Analysis of T1, T2, and Mature B Cells

		Mature	T1	T2 and MZ
Control	spleen	3	3	15
	bone marrow	5	5	—
CD45	spleen	3	2	33
	bone marrow	5	3	—
CBA/N	spleen	4	3	21
	bone marrow	7	5	—

		Mature	T1 and MZ	T2
Control	spleen	3	1	17
CD45	spleen	4	1	31
CBA/N	spleen	4	4	31

Top: spleen and bone marrow cells were stained with Abs to IgM and CD21. After ethanol fixation, propidium iodide was used to label DNA. For cell cycle analysis, cells were gated in T1, T2, and M, as indicated in Fig. 1 B, and the DNA content was measured in these subpopulations. In bone marrow, T2 B cells are undetectable. Percentages of B cells in the G2–M phase of the cell cycle are given.

Bottom: splenic cells were stained with Abs to IgM and IgD before DNA labeling. T1, MZ, T2, and mature B cells were identified as described in the text.

of short-lived B cells, whereas long-lived B cells are mostly unlabeled. The absolute numbers of these cell populations in the spleen are given in Table II. We also calculated the number of labeled B cells that were still detectable 18 d after the BrdU pulse and that, as we have seen, correspond to the small percentage of short-lived B cells that were recruited into the long-lived pool. In CBA/N mice, the number of short-lived splenic B cells was identical to the number in control mice, but in CD45<sup>-/-</sup> mice, it was sevenfold higher. The total number of long-lived cells is normal in CD45 mutant mice but reduced sixfold in CBA/N mice. Accordingly, the number of B cells that entered the long-lived pool was significantly reduced in CBA/N mice but normal in CD45<sup>-/-</sup> mice (Table II).

The short life span of a major part of B cells in the mutant mice and the low fraction of cells that enter the long-lived pool implies that the death rate is very high among these cells. We measured the fraction of apoptotic cells in normal and mutant mice with merocyanine 540, a pigment that binds to the membranes of cells in the early phases of the apoptotic process (31, 32). Whereas only 10% of the T2 B cells bound merocyanine in the normal spleen, 30% of them were apoptotic in CD45<sup>-/-</sup> mice and 25% were apoptotic in CBA/N mice (data not shown).

In conclusion, BrdU labeling experiments and cell cycle analysis confirm that the defects in CD45<sup>-/-</sup> and CBA/N mice are not identical. In CD45<sup>-/-</sup> mice, B cells extensively proliferate at the T2 stage in the spleen, but the number of long-lived B cells is normal. In CBA/N mice, the apparent

**Table II.** Absolute and Relative Numbers of Short- and Long-lived B Cells in the Spleens of Normal and Mutant Mice


	Short-lived	Long-lived	Short→long-lived
Control	5.6 (100%)	29.4 (100%)	0.9 (100%)
CD45 <sup>-/-</sup>	37.8 (670%)	46.2 (157%)	0.8 (89%)
CBA/N	5.2 (92%)	4.8 (16%)	0.1 (11%)

The absolute number ( $\times 10^6$ ) of labeled (short-lived) and unlabeled (long-lived) B cells in the spleens of control, CD45<sup>-/-</sup>, and CBA/N mice was calculated after 3 d of continuous treatment with BrdU. The number of labeled B cells detected 18 d after the 3-d BrdU treatment period corresponds to the number of B cells that became long lived. Numbers of labeled and unlabeled B cells in mutant mice are given in parentheses as percentages of the numbers found in control mice (control = 100%).

increase of T2 B cells is due instead to the reduction of the long-lived mature B cells. In addition, in both mutant mice, long-lived B cells had an abnormal phenotype, showing that the ability to survive can be dissociated from the phenotype in mutant B cells.

*The BCR Is Indispensable for the Development of T2 and Mature B Cells.* It has been suggested that B cells are selected into the mature B cell pool by antigen (8–11). Selection, therefore, would depend on the engagement of the BCR. To analyze the role of the BCR in the development of T1, T2, and mature B cells, we analyzed the late stages of B cell development in mb1  $\Delta c/\Delta c$  mice (12). These mice have a complete deletion of the cytoplasmic tail of the Ig- $\alpha$  component of the BCR, which causes a severe block in the development of peripheral B cells (12). In the spleens of these mice, the number of T1 B cells is 20% of normal, but T2, mature, and MZ B cells are undetectable (Fig. 8, left). This finding confirms that the signaling function of the BCR is essential for the development of T2, mature, and MZ B cells from T1 B cells.

To prove that development of T2 B cells requires signaling through the BCR, we backcrossed CD45<sup>-/-</sup> to mb1/ $\Delta c/\Delta c$  mice. In double-deficient mice, the enlarged T2

**Figure 8.** Development of T2 and mature B cells is blocked in mice lacking the cytoplasmic tail of Ig- $\alpha$ . Spleen cells of mb1  $\Delta c/\Delta c$  (left), CD45<sup>-/-</sup> (center), and mb1  $\Delta c/\Delta c$ -CD45<sup>-/-</sup> double-mutant (right) mice were stained with Abs to CD21 and IgM. Flow cytometric profiles are shown. Dead cells, which fail to exclude the dye propidium iodide, were excluded from the analysis. 100,000 events were collected.

population present in the spleens of CD45<sup>-/-</sup> mice does not develop (Fig. 8; compare CD45<sup>-/-</sup> and double mutant). This indicates that a BCR-mediated signal is required for the development and proliferation of T2 B cells in the spleens of CD45<sup>-/-</sup> mice.

*Primary Follicles of Mutant Mice Show a Normal Architecture.* To study splenic architecture in the mutant mice, we stained spleen sections with Abs against MAdCAM-1, a mucosal vascular addressin that is expressed on the cells lining the marginal sinus in the spleen (33). B cells were labeled with anti-IgM Abs (Fig. 9). In the spleen of the control mouse, the primary follicle (F) is surrounded by a thin layer of MAdCAM-1-positive endothelial cells (green; indicated by arrows). MZ B cells (MZ) express high amounts of IgM and encircle the follicle (F) outside of the marginal sinus. Follicles of CD45<sup>-/-</sup> mice have a larger size but a normal distribution of MZ and follicular B cells. MZ and follicular B cells also have a normal distribution in the spleens of CBA/N mice (34). CBA/N mice, however, have very small lymphoid follicles. The normal distribution of B cells in the spleens of mutant mice shows that their T2 B cells can enter the follicle and that the MZ has a normal proportion, in accordance with the normal fraction of these cells in the spleen.


## Discussion

The differentiation pathway from stem cell to mature B lymphocyte can be divided into several stages, characterized by differentiation processes, proliferation phases, and control steps. The progression of B cells along this pathway is probably best understood assuming that it is governed by the principle of conditional survival. In each developmental stage, specific genetic programs are completed in discrete

environments. To progress from one stage to the next, the cells have to meet specific requirements set by the new developmental stage and the new environment. In the early phases of differentiation in the bone marrow, the ability to productively rearrange the H and L chain genes is an essential requirement (35). The signaling function of the BCR plays an equally important role (36). It has recently been shown that the presence of the BCR is also indispensable for the survival of mature B cells in the periphery (37). This study suggests that the mere presence of the signaling complex organized around the IgM and IgD molecules generates a tonic signal necessary for the survival of mature B cells. It could not, however, address the question of whether this minimal constitutive signal is also sufficient to induce the differentiation of B cells recently generated in the bone marrow into mature B cells.

Studies of B lymphocyte population dynamics have shown that entry into the pool of the mature long-lived B cells is a highly selective event. Only 1–3% of the B lymphocytes leaving the bone marrow every day enter the pool; the remainder of the newly generated B cells are eliminated (5, 11, 38). The requirements that B cells have to meet at the time of selection into the long-lived pool and the site where selection takes place are largely unknown. We show here that selection into the mature pool is an active process and takes place in the spleen. Two populations of splenic B cells were identified as precursors for mature B cells, the T1 and the T2 B cells. Their development into mature B cells requires defined qualitative and quantitative signals derived from the BCR. We finally show that the induction of longevity and maturation requires different signaling pathways.

*A Functional BCR Is Indispensable for the Progression from T1 to T2 and Mature B Cell Stage in the Spleen.* In the spleen, we have identified four different B cell populations by flow cy-



**Figure 9.** Primary follicles of mutant mice show normal architecture. Cryostatic sections of spleens from normal and mutant mice were stained with TRITC-labeled goat anti-mouse IgM Abs. Anti-MAdCAM-1 Abs (from rats) were counterstained with FITC-labeled goat anti-rat Abs. Green and red fluorescence was measured separately by confocal laser microscopy, and the pictures obtained were then overlaid (magnification 100). The arrow points to the thin layer of MAdCAM-1-positive endothelial cells of the marginal sinus. F, follicle.

tometry: T1, T2, mature, and MZ B cells. Their phenotypes are summarized in Table III. T1 B cells originate from the bone marrow and can be detected in the marrow, blood, and spleen but not in the lymph nodes (Fig. 1 A). Entry into the lymph nodes depends on the expression of the homing receptor I-selectin (CD62L) (26). In both mice treated with anti-I-selectin Ab (MEL-14 Ab) (39) and mice deficient for I-selectin (40), the number of B and T cells is drastically reduced in the lymph nodes but is increased in the spleen. Our observations are in accordance with these reports: T1 B cells lack the expression of I-selectin (Fig. 1 A) and home to the spleen, not to the lymph nodes. They enter the spleen via the terminal arterioles of the red pulp and marginal sinus (41). B cells that do not express CD21 and I-selectin have recently been described as non-circulating B cells in the blood. This subset of B cells only homed to the spleen and was excluded from the lymphatic recirculation pathway (42). These cells are probably T1 B cells in transit from the bone marrow to the spleen.

In normal mice, T2 B cells are only found in the spleen. Phenotypically, they appear to be an intermediate stage of differentiation between the T1 and the mature B cell stage. Like T1 B cells, they still express high amounts of the early hematopoietic marker HSA (5) and the recently described marker of immature B cells (43), recognized by the mAb 493 (our unpublished observations). Like mature B cells, they express IgD, CD23, and I-selectin. T2 B cells appear in an activated state *in vivo*: they are large, they express B7-2 (not shown), and a significant fraction of them is in the G2-M phase of the cell cycle (Table I).

MZ B cells are also found in the spleen, in a specialized area that surrounds the white pulp outside the marginal sinus (44), and are phenotypically different from T1 and T2 B cells (Fig. 1, C and D). MZ B cells are noncirculating, long-lived B cells (45).

To establish the ontogenetic order of appearance of T1, T2, and mature B cells, we injected T1 B cells intravenously into RAG-2<sup>-/-</sup> mice. T1 B cells developed into T2 and mature B cells 48 h after the injection into adult RAG-2<sup>-/-</sup> mice (Fig. 2 B). This experiment demonstrates that T1 B cells are the precursors of T2 and mature B cells but

does not establish the developmental relationship between T2 and mature B cells. T2 and mature B cells could represent two independent, end-stage populations generated from the T1 pool. The relatively immature phenotype of T2 B cells and their exclusive presence in the spleen, the only organ where T1 are also found, however, suggest another possible scenario: T2 B cells may represent a developmental checkpoint between T1 and mature B cells. To study the fate of T2 B cells, we transferred them into RAG-2<sup>-/-</sup> mice. T2 B cells developed into mature B cells in 24 h (Fig. 3). Our data shows that T2 B cells represent an intermediate stage of development that feeds into the mature pool. However, we cannot and will not exclude the possibility that at least a fraction of the T1 B cells can directly develop into mature B cells.

T1 and T2 B cells are found in different microenvironments in the spleen. T1 B cells are located in the red pulp and the outer PALS, whereas T2 and mature B cells are located in the follicle (Fig. 4). The development of T2 and mature B cells from T1 precursors and their specific localization in different microenvironments in the spleen might be influenced by the signaling capacity of the BCR. Indeed, it was recently demonstrated that B cells deficient for Syk, a tyrosine kinase that plays a fundamental role in BCR signaling, migrate from the bone marrow to the spleen but fail to enter the primary follicle and remain in the red pulp and the PALS (46). In addition, it has been shown that encounter with antigen influences the migration of B cells from the outer PALS to the follicle (47). It is therefore likely that T1 B cells can enter the primary follicle only if they received a signal in the outer PALS and became T2 B cells. Because entrance into the primary follicles of the spleen is impaired in B cells of mice deficient for the chemokine BLR-1 (48), it is possible that B cells acquire the ability to respond to BLR-1 at the T2 stage.

To analyze the role of the signaling capacity of the BCR in this phase of development, we have studied mice with genetic defects of signaling elements involved in the BCR pathway. In mice lacking the cytoplasmic tail of Ig- $\alpha$  (mb1  $\Delta c/\Delta c$  mice), the signaling function of the BCR is severely impaired. The number of B cells in the bone marrow is reduced to 20% of normal (12). We show here that B cells in the spleen are arrested at the T1 stage of development (Fig. 8). These findings demonstrate that the final steps of B cell development in the spleen, from T1 to T2, mature, and MZ B cells require a functional BCR. The fact that the early stages of B cell development are impaired in the bone marrow of mb1  $\Delta c/\Delta c$  mice, whereas the late stages are completely abolished in the spleen, may reflect a more strict requirement for a perfectly functional BCR in the final phases of differentiation.

In mice deficient for the tyrosine phosphatase CD45, B cells with a proper mature phenotype are missing, whereas the T2 population is six- to eightfold larger than in normal mice (Table II). T2 B cells proliferate in the spleens of CD45<sup>-/-</sup> mice. At least 30% of them are in the G2-M phase of the cell cycle. Surprisingly, also in normal and CBA/N mice, 15–20% of the T2 B cells are in the G2-M phase (Ta-

**Table III.** Phenotypic Description and Tissue Distribution of Immature, T1, T2, Mature, and MZ B Cells

	IMM	T1	T2	M	MZ
IgM	+	+++	+++	+	+++
IgD	-	-	+++	+++	-
CD21	-	-	+++	++	+++
CD23	-	-	++	++	-
Location	BM	BM, B, S	S	BM, B, S, LN	S

Expression of the indicated markers is given as negative (-), weakly positive (+), positive (++), and strongly positive (+++). The location where the various cell types are found is also indicated: bone marrow (BM), blood (B), spleen (S), and lymph nodes (LN). IMM, immature.



receive a strong signal upon binding, are deleted. Positive selection in the mature pool may happen at a much lower signaling threshold, at a level where the quality and composition of the BCR signal transduction apparatus is of fundamental importance.

This model predicts that B cells expressing certain V region specificities would be selected only into the T2 or MZ pools and never into the mature pool and vice versa. Indeed, previous findings are compatible with this view. In mice, where the rearranged T15 V<sub>H</sub> region gene was introduced in its natural location, 5' of the Ig intron enhancer, all B cells expressed the transgenic V<sub>H</sub> region in their Abs. Splenic B cells had the phenotype of T2 B cells, and the mature population was absent (55). In a transgenic mouse model, it has recently been shown that B cells expressing a multireactive IgM transgene derived from fetal liver B cells are selected into the MZ (56) but do not become mature B cells.

What is the ligand that drives the B cells during the last stages of differentiation? We do not have an answer to this important question. In germ-free mice, the number of mature B cells is strongly reduced, whereas the number of T2 B cells is normal (data not shown). T cells are not necessary for the development of T2 and mature B cells, because both populations are present in mice unable to generate T cells (data not shown). Large, activated B cells have been previously described in the spleens of normal mice and were called naturally activated B cells. They are probably generated by the low-affinity interaction with autoantigens. Naturally activated B cells are thought play an important role in the construction of the B cell repertoire and secrete the natural antibodies found in the sera of mice and humans (57, 58). Natural Abs play a role in the defence against

common pathogens and may represent a linkage between innate and adaptive immunity (59). T2 B cells might be identical to this population. Alternatively, T2 B cells could have a function in the first-line, rapid, and thymus-independent defense against infectious agents. Recruitment of T2 B cells in this type of immune response might be facilitated by the preactivated state of this cell type by the high density of the BCR and complement receptors. In agreement with this possibility, encapsulated bacteria, which induce a rapid thymus-independent immune response in normal individuals, cause a life-threatening disease in splenectomized and hyposplenic patients. This acute form of sepsis, known as OPSI (overwhelming post-splenectomy infection), frequently results in the death of the patient (60).

The identification of two new stages of B cell development in the spleen allows a better definition of the phenotype of mice with defects of the BCR signaling pathway. Indeed, a survey of the published data suggests that B cell development may be blocked at the T1 stage in Syk-deficient mice (46) but at the T2 stage in both Lyn (61, 62) and Vav mutant (63, 64) mice (Fig. 10). The role of the spleen in the development of T2 and mature B cells can be studied thanks to the availability of mice lacking spleens or having severely altered splenic architecture.

Finally, preliminary experiments have shown that T2 B cells are also present in the human spleen and, under certain pathophysiological conditions, also outside of the spleen. Our study should help provide a better understanding of the rules and signals that regulate B cell survival, differentiation, and activation in health and disease in mice and in humans.

---

We thank Dr. Horst Mossmann and Mrs. Uta Stauffer for their invaluable help with the maintenance and breeding of animals and Drs. Roberta Pelanda and Thomas Boehm for critically reading the manuscript.

This work was funded in part by a Deutsche Forschungsgemeinschaft grant (Leibniz Prize to Dr. Michael Reth). B. Mutschler and R. Carsetti are supported by a grant from the Deutsche Krebshilfe (Mildred Scheel Stiftung, Germany).

Address correspondence to Rita Carsetti, Max-Planck-Institute for Immunobiology, Stübeweg 51, D-79108 Freiburg, Germany. Phone: 49-761-5108-244; Fax: 49-761-5108-333; E-mail: carsetti@immunbio.mpg.de

Present addresses are as follows: F. Loder, Howard Florey Institute, University of Melbourne, Melbourne 3052, Australia; R.J. Ray and C.J. Paige, Ontario Cancer Institute, Toronto, Ontario M5G 2C1, Canada.

*Submitted: 16 November 1998 Revised: 22 April 1999 Accepted: 5 May 1999*

## References

1. Rolink, A., and F. Melchers. 1996. B-cell development in the mouse. *Immunol. Lett.* 54:157-161.
2. Reth, M. 1995. The B-cell antigen receptor complex and co-receptors. *Immunol. Today.* 16:310-313.
3. Carsetti, R., G. Kohler, and M.C. Lamers. 1995. Transitional B cells are the target of negative selection in the B cell compartment. *J. Exp. Med.* 181:2129-2140.
4. Jacobsen, K., and D.G. Osmond. 1990. Microenvironmental organization and stromal cell associations of B lymphocyte precursor cells in mouse bone marrow. *Eur. J. Immunol.* 20: 2395-2404.
5. Allman, D.M., S.E. Ferguson, V.M. Lentz, and M.P. Cancro. 1993. Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate

- in the production of long-lived marrow-derived B cells. *J. Immunol.* 151:4431–4444.
6. Melchers, F., A. Rolink, U. Grawunder, T.H. Winkler, H. Karasuyama, P. Ghia, and J. Andersson. 1995. Positive and negative selection events during B lymphopoiesis. *Curr. Opin. Immunol.* 7:214–227.
  7. Yuan, D., and P.L. Witte. 1988. Transcriptional regulation of mu and delta gene expression in bone marrow pre-B and B lymphocytes. *J. Immunol.* 140:2808–2814.
  8. Gu, H., D. Tarlinton, W. Muller, K. Rajewsky, and I. Forster. 1991. Most peripheral B cells in mice are ligand selected. *J. Exp. Med.* 173:1357–1371.
  9. Rajewsky, K. 1996. Clonal selection and learning in the antibody system. *Nature.* 381:751–758.
  10. Viale, A.C., A. Coutinho, R.A. Heyman, and A.A. Freitas. 1993. V region dependent selection of persistent resting peripheral B cells in normal mice. *Int. Immunol.* 5:599–605.
  11. Coutinho, A. 1993. Lymphocyte survival and V-region repertoire selection. *Immunol. Today.* 14:38–40.
  12. Torres, R.M., H. Flaswinkel, M. Reth, and K. Rajewsky. 1996. Aberrant B cell development and immune response in mice with a compromised BCR complex. *Science.* 272:1804–1808.
  13. Kishihara, K., J. Penninger, V.A. Wallace, T.M. Kundig, K. Kawai, A. Wakeham, E. Timms, K. Pfeffer, P.S. Ohashi, M.L. Thomas, et al. 1993. Normal B lymphocyte development but impaired T cell maturation in CD45-exon 6 protein tyrosine phosphatase-deficient mice. *Cell.* 74:143–156.
  14. Benatar, T., R. Carsetti, C. Furlonger, N. Kamalia, T. Mak, and C.J. Paige. 1996. Immunoglobulin-mediated signal transduction in B cells from CD45-deficient mice. *J. Exp. Med.* 183:329–334.
  15. Pao, L.L., and J.C. Cambier. 1997. Syk, but not Lyn, recruitment to B cell antigen receptor and activation following stimulation of CD45<sup>-</sup> B cells. *J. Immunol.* 158:2663–2669.
  16. Rawlings, D.J., and O.N. Witte. 1995. The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function. *Semin. Immunol.* 7:237–246.
  17. Yao, L., Y. Kawakami, and T. Kawakami. 1994. The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C. *Proc. Natl. Acad. Sci. USA.* 91:9175–9179.
  18. Tsukada, S., M.I. Simon, O.N. Witte, and A. Katz. 1994. Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase. *Proc. Natl. Acad. Sci. USA.* 91:11256–11260.
  19. Bolland, S., R.N. Pearce, T. Kurosaki, and J.V. Ravetch. 1998. SHIP modulates immune receptor responses by regulating membrane association of Btk. *Immunity.* 8:509–516.
  20. Satterthwaite, A.B., Z. Li, and O.N. Witte. 1998. Btk function in B cell development and response. *Semin. Immunol.* 10:309–316.
  21. Thomas, J.D., P. Sideras, C.I. Smith, I. Vorechovsky, V. Chapman, and W.E. Paul. 1993. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. *Science.* 261:355–358.
  22. Scher, I., J.A. Titus, and F.D. Finkelman. 1983. The ontogeny and distribution of B cells in normal and mutant immune-defective CBA/N mice: two-parameter analysis of surface IgM and IgD. *J. Immunol.* 130:619–625.
  23. Khan, W.N., F.W. Alt, R.M. Gerstein, B.A. Malynn, I. Larsson, G. Rathbun, L. Davidson, S. Muller, A.B. Kantor, L.A. Herzenberg, et al. 1995. Defective B cell development and function in Btk-deficient mice. *Immunity.* 3:283–299.
  24. Shinkai, Y., G. Rathbun, K.-P. Lam, E.M. Oltz, V. Stewart, M. Mendelsohn, J. Charron, M. Datta, F. Young, A.M. Stall, et al. 1992. RAG-2 deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. *Cell.* 68:855–867.
  25. Melamed, D., R.J. Benschop, J.C. Cambier, and D. Nemazee. 1998. Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection. *Cell.* 92:173–182.
  26. Tedder, T.F., D.A. Steeber, A. Chen, and P. Engel. 1995. The selectins: vascular adhesion molecules. *FASEB J.* 9:866–873.
  27. Fearon, D.T., and R.H. Carter. 1995. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. *Annu. Rev. Immunol.* 13:127–149.
  28. Oliver, A.M., F. Martin, G.L. Gartland, R.H. Carter, and J.F. Kearney. 1997. Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. *Eur. J. Immunol.* 27:2366–2374.
  29. Monroe, J.G. 1996. Tolerance sensitivity of immature-stage B cells: can developmentally regulated B cell antigen receptor (BCR) signal transduction play a role? *J. Immunol.* 156:2657–2660.
  30. Forster, I., and K. Rajewsky. 1990. The bulk of the peripheral B-cell pool in mice is stable and not rapidly renewed from the bone marrow. *Proc. Natl. Acad. Sci. USA.* 87:4781–4784.
  31. McEnvoy, L., R.A. Schlegel, P. Williamson, and B.J. Del Buono. 1988. Merocyanine 540 as a flow cytometric probe of membrane lipid organization in leukocytes. *J. Leukoc. Biol.* 44:337–344.
  32. Mower, D.A.J., D.W. Peckham, V.A. Illera, J.K. Fishbaugh, L.L. Stunz, and R.F. Ashman. 1994. Decreased membrane phospholipid packing and decreased cell size precede DNA cleavage in mature mouse B cell apoptosis. *J. Immunol.* 152:4832–4842.
  33. Kraal, G., K. Schornagel, P.R. Streeter, B. Holzmann, and E.C. Butcher. 1995. Expression of the mucosal vascular addressin, MAdCAM-1, on sinus-lining cells in the spleen. *Amer. J. Pathol.* 144:763–771.
  34. Liu, Y.J., J.E. Lortan, S. Oldfield, and I.C. MacLennan. 1988. CBA/N mice have marginal zone B cells with normal surface immunoglobulin phenotype. *Adv. Exp. Med. Biol.* 237:105–111.
  35. Chen, J., and F.W. Alt. 1993. Gene rearrangement and B-cell development. *Curr. Opin. Immunol.* 5:194–200.
  36. Turner, M., P.J. Mee, P.S. Costello, O. Williams, A.A. Price, L.P. Duddy, M.T. Furlong, R.L. Geahlen, and V.L. Tybulewicz. 1995. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. *Nature.* 378:298–302.
  37. Lam, K.P., R. Kuhn, and K. Rajewsky. 1997. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. *Cell.* 90:1073–1083.
  38. Rolink, A., D. Haasner, F. Melchers, and J. Andersson. 1996. The surrogate light chain in mouse B-cell development. *Int. Rev. Immunol.* 13:341–356.
  39. Lepault, F., M.C. Gagnerault, C. Faveeuw, and C. Boitard. 1994. Recirculation, phenotype and functions of lymphocytes in mice treated with monoclonal antibody MEL-14. *Eur. J. Immunol.* 24:3106–3112.
  40. Arbones, M.L., D.C. Ord, K. Ley, H. Rotech, C. Maynard-

- Curry, G. Otten, D.J. Capon, and T.F. Tedder. 1994. Lymphocyte homing and leukocyte rolling and migration are impaired in I-selectin-deficient mice. *Immunity*. 1:247–260.
41. MacLennan, J. 1998. B-cell development of peripheral B cells. *Curr. Opin. Immunol.* 10:220–225.
  42. Young, A.J., W.L. Marston, M. Dessing, L. Dudler, and W.R. Hein. 1997. Distinct recirculating and non-recirculating B-lymphocyte pools in the peripheral blood are defined by coordinated expression of CD21 and I-selectin. *Blood*. 90:4865–4875.
  43. Rolink, A.G., J. Andersson, and F. Melchers. 1998. Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity. *Eur. J. Immunol.* 28:3738–3748.
  44. Kumararatne, D.S., and I.C. MacLennan. 1981. Cells of the marginal zone of the spleen are lymphocytes derived from recirculating precursors. *Eur. J. Immunol.* 11:865–869.
  45. MacLennan, I.C., Y.J. Liu, S. Oldfield, J. Zhang, and P.J. Lane. 1990. The evolution of B-cell clones. *Curr. Top. Microbiol. Immunol.* 159:37–63.
  46. Turner, M., A. Gulbranson-Judge, M.E. Quinn, A.E. Walters, I.C. MacLennan, and V.L. Tybulewicz. 1997. Syk tyrosine kinase is required for the positive selection of immature B cells into the recirculating B cell pool. *J. Exp. Med.* 186:2013–2021.
  47. Fulcher, D.A., and A. Basten. 1997. B-cell activation versus tolerance—the central role of immunoglobulin receptor engagement and T-cell help. *Int. Rev. Immunol.* 15:33–52.
  48. Forster, R., A.E. Mattis, E. Kremmer, E. Wolf, G. Brem, and M. Lipp. 1996. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. *Cell*. 87:1037–1047.
  49. Freitas, A.A., and B.B. Rocha. 1993. Lymphocyte lifespans: homeostasis, selection and competition. *Immunol. Today*. 14:25–29.
  50. Ulyanova, T., J. Blasioli, and M.L. Thomas. 1997. Regulation of cell signaling by the protein tyrosine phosphatases, CD45 and SHP-1. *Immunol. Res.* 16:101–113.
  51. Pani, G., K.A. Siminovitch, and C.J. Paige. 1997. The moth-eaten mutation rescues B cell signaling and development in CD45-deficient mice. *J. Exp. Med.* 186:581–588.
  52. Nitschke, L., R. Carsetti, B. Ocker, G. Kohler, and M.C. Lamers. 1997. CD22 is a negative regulator of B-cell receptor signalling. *Curr. Biol.* 7:133–143.
  53. Woodland, R.T., M.R. Schmidt, S.J. Korsmeyer, and K.A. Gravel. 1996. Regulation of B cell survival in *xid* mice by the proto-oncogene *bcl-2*. *J. Immunol.* 156:2143–2154.
  54. Dempsey, P.W., and D.T. Fearon. 1996. Complement: instructing the acquired immune system through the CD21/CD19 complex. *Res. Immunol.* 147:71–75.
  55. Taki, S., M. Meiering, and K. Rajewsky. 1993. Targeted insertion of a variable region gene into the immunoglobulin heavy chain locus. *Science*. 262:1268–1271.
  56. Chen, X., F. Martin, K.A. Forbush, R.M. Perlmutter, and J.F. Kearney. 1997. Evidence for selection of a population of multi-reactive B cells into the splenic marginal zone. *Int. Immunol.* 9:27–41.
  57. Coutinho, A., M.D. Kazatchkine, and S. Avrameas. 1995. Natural autoantibodies. *Curr. Opin. Immunol.* 7:812–818.
  58. Lacroix-Desmazes, S., L. Mouthon, A. Coutinho, and M.D. Kazatchkine. 1995. Analysis of the natural human IgG antibody repertoire: life-long stability of reactivities towards self antigens contrasts with age-dependent diversification of reactivities against bacterial antigens. *Eur. J. Immunol.* 25:2598–2604.
  59. Carroll, M.C., and A.P. Prodeus. 1998. Linkages of innate and adaptive immunity. *Curr. Opin. Immunol.* 10:36–40.
  60. Reid, M.M. 1994. Splenectomy, sepsis, immunization and guidelines. *Lancet*. 344:970–971.
  61. Wang, J., T. Koizumi, and T. Watanabe. 1996. Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in *Lyn*-deficient mice. *J. Exp. Med.* 184:831–838.
  62. Chan, V.W., F. Meng, P. Soriano, A.L. DeFranco, and C.A. Lowell. 1997. Characterization of the B-lymphocyte populations in *Lyn*-deficient mice and the role of *Lyn* in signal initiation and downregulation. *Immunity*. 7:69–81.
  63. Tarakhovsky, A., M. Turner, S. Schaal, P.J. Mee, L.P. Duddy, K. Rajewsky, and V.L. Tybulewicz. 1995. Defective antigen receptor-mediated proliferation of B and T cells in the absence of *Vav*. *Nature*. 374:467–470.
  64. Zhang, R., F.W. Alt, L. Davidson, S.H. Orkin, and W. Swat. 1995. Defective signalling through the T- and B-cell antigen receptors in lymphoid cells lacking the *vav* proto-oncogene. *Nature*. 374:470–473.